ENGOT-Ov41/GEICO-69-O/ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp) >6 months.
Authors:
- 20 May 2019
- journal article
- conference paper
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , TPS5599